Paroxetine

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Therapy, Addiction, Paroxetine, Anxiety, DMT, Mental health, SP, Imipramine, Artificial intelligence, Tri, Serotonin, BPP, Sleep, MT1, HTR, Aripiprazole, Fenfluramine, MDMA, Trazodone, Human, Mammal, Patient, Hallucination, Melatonin, DSM-IV codes, Plasma, ADHD, Literature, Research, Nefazodone, Mouse, Depression, Pharmaceutical industry

“As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.

Key Points: 
  • “As a result, Enveric now possesses what we believe to be one of the most diverse portfolios of potential drug molecules for the treatment of key, underserved mental health and neurological disorders.
  • Enveric SNDRI compounds also demonstrate distinct additional serotonin receptor binding profiles that bear similarities to those of the antidepressant Nefazodone and the anxiolytic Buspirone.
  • Enveric NSRI compounds show strong binding to SERT, as well as to the 5-HT1A receptor, known to be a therapeutically valuable target.
  • For more information about Enveric’s novel preclinical compounds spanning multiple, distinct classes of molecules, please visit: https://www.enveric.com/psybrary .

Ketamine can rapidly reduce symptoms of PTSD and depression, new study finds

Retrieved on: 
Wednesday, November 8, 2023
Post-traumatic stress disorder, Patient, Ketamine, Suicide, Grammatical mood, Research, Survivor, Time, Food, Nightmare, Child abuse, Sertraline, Annals of Pharmacotherapy, Injection, Psychotherapy, Veteran, Trauma, Meta-analysis, PTSD, Disorder, Disease, Assault, LSD, Pharmacy, Population, Paroxetine, Depression, Anxiety, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Vaccine, Meat

The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.

Key Points: 
  • The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection.
  • Patients receiving ketamine saw their PTSD symptoms reduced by about 25% both at one day and one week after therapy.
  • Ketamine might be an effective bridge to immediately reduce patients’ symptoms until trauma-focused psychotherapy and other antidepressants can kick in.
  • What still isn’t known
    The big unknown with using ketamine for PTSD and depressive symptoms is how often the injections are needed.

Lifeist's Mikra Completes Formulation of Innovative Mental Health Product for Anxiety 

Retrieved on: 
Thursday, November 2, 2023
Taste, Science, Sale, Selective serotonin reuptake inhibitor, Seizure, GCMS, Weight gain, Anxiety, Research, Hélder Morim, Paroxetine, GAD, SSRI, Anxiety disorder, Patient, Benzodiazepine, Pharmaceutical industry, Serenity

This innovation complements our successful CELLF product, reflecting our commitment to advancing holistic wellness solutions."

Key Points: 
  • This innovation complements our successful CELLF product, reflecting our commitment to advancing holistic wellness solutions."
  • "Anxiety disorders are widespread, affecting 40 million adults in the U.S. alone, yet a significant portion of this population remains untreated.
  • Serenity is poised to make a meaningful impact in enhancing mental well-being, aligning with our vision of improving lives through cellular health."
  • Mikra takes pride in introducing Serenity, which will be available for sale on weareMikra.com before the December holiday season.

The Menopause Society Annual Meeting 2023: Bayer to present latest real-world evidence of menopausal symptoms and their treatment

Retrieved on: 
Wednesday, September 27, 2023
Women, Biotechnology, Pharmaceutical, Managed Care, Oncology, General Health, Health, Consumer, Contraindication, Benzodiazepine, VMS, North American Menopause Society, Education, HT, Woman, Research, ET, Paroxetine, RWE, Breast cancer, Birth control, Pharmaceutical industry, Dietary supplement, Bayer

Bayer will present the latest RWE research results which focuses on treatment utilization and pathways in women with menopausal symptoms at the upcoming Menopause Society Annual Meeting (formerly The North American Menopause Society).

Key Points: 
  • Bayer will present the latest RWE research results which focuses on treatment utilization and pathways in women with menopausal symptoms at the upcoming Menopause Society Annual Meeting (formerly The North American Menopause Society).
  • The Menopause Society Annual Meeting takes place from September 27 – 30, in Philadelphia, Pennsylvania, USA.
  • Key Highlights of Bayer’s presentations at The Menopause Society annual meeting 2023 are:
    REALISE iVMS: What do women with breast cancer take for menopause symptoms?
  • Two-thirds of natural menopausal women did not receive treatment for menopausal symptoms, which might suggest undertreatment in this population.

Psychedelics may better treat depression and anxiety symptoms than prescription antidepressants for patients with advanced cancer

Retrieved on: 
Monday, April 17, 2023
People, Psilocybin, Blood pressure, Review, Trauma, Escitalopram, Drug, Drug Enforcement Administration, Depression, Paroxetine, Senior counsel, Anxiety, Placebo, Cancer, Ground substance, Schedule 1, Research, Emotion, LSD, Meta-analysis, History, Fluoxetine, Schedule, Food and Drug Administration Amendments Act of 2007, Patient, Catharsis, Grammatical mood, Caregiver, FDA, Bias, MDMA, Food, PTSD, Pharmaceutical industry, Nightclub, Meat, Cannabidiol

In people with advanced cancer, psychedelic drugs like psilocybin, LSD and MDMA may significantly reduce the severity of depression and anxiety symptoms.

Key Points: 
  • In people with advanced cancer, psychedelic drugs like psilocybin, LSD and MDMA may significantly reduce the severity of depression and anxiety symptoms.
  • However, current research suggests that available prescription antidepressants do not significantly decrease depressive symptoms in cancer patients compared with a placebo.
  • My team and I recently completed a meta-analysis of five clinical trials examining anxiety and depression symptoms in patients with advanced forms of cancer and other life-threatening diseases.

Psychedelics and trauma

    • People who develop PTSD from military service or physical or sexual violence commonly experience depression and anxiety.
    • Based on this research, my team and I hypothesize that psychedelic sessions might have an advantage over traditional prescription antidepressants for patients with cancer-related depression or anxiety because it may help them deal with their underlying trauma.
    • Patients stated that the psychedelic sessions helped them process the intense feelings they were repressing without being overwhelmed.

Unknowns in psychedelic therapy

    • A number of the advanced cancer studies we examined included people with a history of psychedelic use.
    • People with prior positive recreational psychedelic experiences may be more likely to participate in these studies than those who experienced a “bad trip” or were opposed to recreational drugs altogether.
    • Additionally, even though the placebo was made to look identical, it is unlikely that patients or caregivers were fooled if it did not elicit a psychedelic effect.

Next steps for psychedelics

    • More research is needed on effectiveness of psychedelics to treat anxiety and depression in cancer patients.
    • Exploring psychedelic treatments for patients with other life-threatening diseases that cause trauma, anxiety or depression could clarify their potential therapeutic benefits.
    • Were the Food and Drug Administration to approve psychedelics for this kind of use, the agency would need to figure out how these psychedelics can be used legally.

FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder

Retrieved on: 
Thursday, March 30, 2023
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Columbia University, Depression, Central nervous system, Paroxetine, Sertraline, Liebowitz social anxiety scale, Anxiety, New Drug Application, Fear, Fasedienol, Clinical trial, NDA, SAD, Headache, CNS, New York State Psychiatric Institute, Trial of the century, Hamilton Anxiety Rating Scale, PRN, DSM-IV codes, Disorder, Patient, LSAS, Anxiety disorder, Social anxiety disorder, Principal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Nursing, Ajda

“With positive feedback from the FDA, we’re focused on advancing a clinical study design with the Liebowitz Social Anxiety Scale as the primary endpoint to study the real-world effects of fasedienol over time,” said Shawn Singh, Chief Executive Officer of Vistagen.

Key Points: 
  • “With positive feedback from the FDA, we’re focused on advancing a clinical study design with the Liebowitz Social Anxiety Scale as the primary endpoint to study the real-world effects of fasedienol over time,” said Shawn Singh, Chief Executive Officer of Vistagen.
  • “This is an important step forward, especially as SAD is becoming even more prevalent in a post-COVID world.
  • Dr. Liebowitz was among the clinical investigators involved in the registrational efficacy trials for all of these drugs, and all of such registrational trials were positive.
  • Results of the AjDA study may provide support for an as-needed (PRN) fasedienol dosing approach over time as the preferred mode of treatment.

Spaulding Clinical and FDA Study Contributing to Efforts to Address Opioid Crisis

Retrieved on: 
Wednesday, January 25, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Human, American Medical Association, Paroxetine, Oxycodone, Hypercapnia, Carbon, Depression, Clinical trial, Food, Risk, Anxiety, Death, SSRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hypoventilation, Ventilation, Pharmaceutical industry, Medical device

Spaulding Clinical , a full-service Phase I clinical service provider, worked with the U.S. Food and Drug Administration (FDA) to conduct a clinical trial as a part of the FDA’s proactive effort to address the opioid crisis and reduce opioid overdoses and deaths.

Key Points: 
  • Spaulding Clinical , a full-service Phase I clinical service provider, worked with the U.S. Food and Drug Administration (FDA) to conduct a clinical trial as a part of the FDA’s proactive effort to address the opioid crisis and reduce opioid overdoses and deaths.
  • This trial evaluated whether two common psychotropic drugs would further decrease ventilation when combined with an opioid compared to an opioid alone.
  • Opioids can decrease ventilatory response to hypercapnia, or excessive carbon dioxide in the bloodstream, which can cause severe respiratory depression or death.
  • Since 2016, the FDA has required boxed warnings for both benzodiazepine and opioid products about increased respiratory depression risk with simultaneous use.

Post-traumatic Stress Disorder Treatment Global Market Report 2022: Increasing R&D by Key Players Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Pharmaceutical, Health, Mental Health, Post-traumatic stress disorder, Administration, Woman, Veteran, Nightmare, Distribution, Paroxetine, Circulatory system, PTSD, Thought, Safety, Jazz Pharmaceuticals, Insomnia, Market, GlobalPost, Patient, Route of administration, Vietnam War, Region, Sudden death, Research, Sertraline, FAAH, Anxiety, Fluoxetine, Marketing, Growth, US, Trauma, American Psychiatric Association, Pharmaceutical industry, Meat

The "Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc.
  • Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.
  • Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period.

Post-traumatic Stress Disorder Treatment Market - Global Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Retrieved on: 
Tuesday, January 24, 2023
Veteran, Safety, GlobalPost, PTSD, American Psychiatric Association, Fluoxetine, Marketing, Nightmare, Post-traumatic stress disorder, Route of administration, Sertraline, Paroxetine, Region, Jazz Pharmaceuticals, US, Insomnia, Growth, FAAH, Trauma, Thought, Sudden death, Market, Vietnam War, Circulatory system, Patient, Woman, Anxiety, Administration, Research, Distribution, Pharmaceutical industry, Meat

DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Post-traumatic stress disorder (PTSD) is a psychiatric condition that may occur in people who have witnessed a traumatic shock like natural disaster, a life threatening event, car accident, sexual abuse etc.
  • Commonly prescribed drugs for post trauma stress disorder includes antidepressants, sertraline, fluoxetine, paroxetine, and others.
  • Increasing research and development activities by the key market players for the treatment of post-traumatic stress disorder is expected to boost the growth of the global post-traumatic stress disorder treatment market over the forecast period.

Antidepressant Tapering Platform Outro Launches in Canada Ahead of World Tapering Day

Retrieved on: 
Tuesday, November 1, 2022
Technology, Mental Health, Health Technology, Software, Health, Pharmaceutical, General Health, Other Science, Science, Awareness, Dizziness, Sertraline, Grammatical mood, Psychotherapy, Citalopram, Method, Serotonin–norepinephrine reuptake inhibitor, Risk, COVID-19, Paroxetine, Headache, Technology, Anxiety, Selective serotonin reuptake inhibitor, Patient, Fluoxetine, Depression, Pharmaceutical industry, Online shopping, Facebook, Outro, Instagram

Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.

Key Points: 
  • Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.
  • Outros user-friendly platform provides science-based, personalized tapering plans to slowly reduce medication dosage.
  • We are incredibly excited to bring this platform to many in need across Canada, said Brandon Goode, co-founder and chief executive officer of Outro.
  • Outro is poised to help many in Canada and eventually more around the world.